Last Updated: May 12, 2026

Panama: These Drugs Face Patent Expirations and Loss of Exclusivity Dates in 2026 - 2027

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Panama

Generic Entry Dates in Other Countries

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Panama: These Drugs Face Patent Expirations and Loss of Exclusivity Dates in 2026 - 2027

Tradename Ingredient Estimated Entry Opportunity Date
ALIQOPA copanlisib dihydrochloride 2027-12-04
>Tradename >Ingredient >Estimated Entry Opportunity Date

Details: Panama: These Drugs Face Patent Expirations and Loss of Exclusivity Dates in 2026 - 2027

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2027
Generic Entry Controlled by: Panama Patent 8,759,601

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-eight countries.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.